Cabergoline therapy for Cushing disease throughout pregnancy.

Abstract

BACKGROUND:

Cushing disease during pregnancy is rare and is associated with significant maternal and fetal morbidity and mortality. Transsphenoidal pituitary surgery is the first-line therapy; however, in cases of failed surgery or in patients who are not surgical candidates, medical therapy has been used to control symptoms.

CASE:

A 29-year-old woman with Cushing disease and a noncurative transsphenoidal pituitary surgery was successfully treated with cabergoline, a dopamine agonist. After approximately 1 year of therapy, she became pregnant. She was maintained on high-dose cabergoline throughout her pregnancy and had an uncomplicated antenatal course. She went into spontaneous labor at 38 weeks of gestation and delivered a healthy female neonate.

CONCLUSION:

Cabergoline can be used to manage Cushing disease successfully during pregnancy with an opportunity for a favorable outcome.

• Authors: Irene Woo, Robert M Ehsanipoor
• Journal: Obstetrics and gynecology (Obstet Gynecol) Vol. 122 Issue 2 Pt 2 Pg. 485-487 (Aug 2013) ISSN: 1873-233X [Electronic] United States
• PMID: 23884269 (Publication Type: Case Reports, Journal Article)

Chemical References

• Dopamine Agonists
• Ergolines
• Cabergoline

Topics

• Adult
• Cabergoline
• Dopamine Agonists (therapeutic use)
• Ergolines (therapeutic use)
• Female
• Humans
• Infant, Newborn
• Live Birth
• Pituitary ACTH Hypersecretion (drug therapy)
• Pregnancy
• Pregnancy Complications (drug therapy)